VASOOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

VASO Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.29+0.00 (+0.06%)

Close on Oct 19, 2026

Market cap: $51.17M
P/E (TTM): 29.0
Dividend yield: –

VASO Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2011 2011-05-31	FY 2010 2010-05-31
Revenue	89	87	81	79	76	70	76	74	73	73	57	35	33	16	4.21
Cost of Revenue	34	35	30	31	32	31	33	33	32	31	22	9.76	10	5.46	1.99
Gross Profit	55	52	51	48	43	39	42	41	41	42	35	25	23	11	2.21
Research & Development	0.73	0.85	0.76	0.61	1.72	0.75	0.81	0.89	0.95	0.53	0.52	0.80	0.69	0.46	0.42
Selling, General & Admin	52	49	45	41	39	37	41	44	44	39	31	23	23	14	3.77
General & Administrative	0.04	0.05	0.08	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	58	52	46	41	40	38	42	45	45	40	31	24	24	15	4.19
Operating Income	-2.89	0.29	4.20	6.45	2.82	0.77	0.59	-3.72	-3.83	1.56	3.94	1.06	-1.29	-3.93	-1.98
Interest & Investment Income	0.79	1.00	0.76	–	–	–	–	–	–	–	–	–	–	–	–
Income from Equity Investments	–	–	–	–	–	0.01	0	-0.01	-0.02	-0.01	0	–	–	–	–
Other Non-Operating Income	1.59	0.99	0.71	0.10	3.43	-0.42	-0.86	-0.40	-0.57	-0.46	-0.16	0.19	0.09	0.05	0.13
Asset Impairment Charges	-4.64	–	–	–	–	–	–	–	0	0	0	–	–	–	–
Gain (Loss) on Investments	-0.41	-0.25	-0.21	-0.15	–	–	0	0.68	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.01	0.00	0.00	0.00	0	0.11	0	0	0.00	0	0	-0.02	0	0	0
Pretax Income	-1.31	1.28	4.91	6.55	6.25	0.36	-0.27	-4.12	-4.41	1.10	3.78	1.26	-1.20	-3.88	-1.85
Income Tax Expense	-2.88	0.33	0.10	-4.74	0.15	0.00	0.11	-0.39	0.13	0.28	-0.04	0.13	-0.06	0.01	-0.04
Net Income incl. Noncontrolling Interests	–	–	–	-12	-6.10	–	–	–	–	–	–	–	–	–	–
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0.08
Net Income	1.57	0.95	4.81	11	6.10	0.36	-0.38	-3.73	-4.54	0.82	3.82	1.13	-1.15	-3.89	-1.82
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	–	–	–	0.43	0
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	-4.32	-1.89
EPS (Basic)(per share)	0.01	0.01	0.03	0.07	0.04	0.00	0.00	-0.02	-0.03	0.01	0.02	0.01	-0.01	-0.04	-0.02
EPS (Diluted)(per share)	0.01	0.01	0.03	0.06	–	0.00	0.00	-0.02	-0.03	0.01	0.02	0.01	-0.01	-0.04	-0.02
Shares Outstanding (Basic, Weighted)(shares)	176	175	174	173	0.17	0.17	0.17	0.17	0.16	159	157	155	159	112	102
Shares Outstanding (Diluted, Weighted)(shares)	176	176	176	175	174	0.17	0.17	0.17	0.16	159	157	156	159	112	102
EBITDA	-2.03	1.11	5.19	8.38	6.66	3.23	3.27	-1.20	-1.41	3.72	5.48	1.53	-0.93	-3.79	-1.86
Provision for Credit Losses	–	–	–	–	–	–	–	–	0	0.41	0	–	–	–	–
Net Investment Income	–	–	–	–	6.10	0.36	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 64.8%
Operating margin: -2.0%
Net margin: 3.1%
Return on equity, FY2025: 5.5%

Financial strength

Current ratio: 1.68
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 116.5%

Valuation

P/E ratio: 29.0
Price to sales: 0.64
Price to book: 1.75
Dividend yield: –